Laprot® (LAPROT®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplyophilizate for solution for infusion and endotracheal administration
Composition:

Active substance: lactoferrin of female milk 50 mg;

adjuvant: sodium chloride 350 mg.

Description:Lyophilized powder is white, odorless.
Pharmacotherapeutic group:Antioxidant
ATX: & nbsp
  • Other medications
    • Pharmacodynamics:

    An antioxidant drug designed for the prevention and management of intoxications of various etiologies.

    The main component of the drug Laproth ® is lactoferrin of female milk, which has antioxidant and immunomodulating properties. In the human body, it has a detoxifying, anti-inflammatory effect.

    Lactoferrin of female milk has a high antioxidant activity, much higher than that of the antioxidant enzyme superoxide dismutase and antioxidant vitamins A, E, C, β-carotene and rutin. High antioxidant activity determines the detoxifying effect of lactoferrin in the body.

    In patients with purulent-inflammatory and septic processes, the intravenous application of the drug Laprot® leads to the normalization of the functional state of various organs and systems of the body:

    - liver and kidneys, which is reflected in a decrease in blood biochemical parameters (bilirubin, transaminases, urea and creatinine);

    - Oxidation-antioxidant system, which is expressed in a decrease in the intensity of lipid peroxidation and increase in the activity of endogenous antioxidants;

    - immune system, which is expressed in the normalization of the morphological parameters of the blood, in particular, in increasing the total number of lymphocytes and normalizing the relative number of lymphocyte subpopulations.

    Intravenous and intracavitary administration of the drug to patients leads to a decrease in the titer of pathogenic microflora in the foci of inflammation.

    Pharmacokinetics:

    The maximum concentration in the blood is 4.3 μg / ml, the half-life of 3 hours.

    Indications:

    Intoxication caused by purulent-inflammatory diseases (as part of complex therapy, intravenous administration).

    Pyoinflammatory complications after reconstructive surgical interventions for cicatricial stenosis of the trachea and after tracheostomy (as part of complex therapy, endotracheal administration).

    Contraindications:

    Individual intolerance of protein preparations.

    Children's age (no studies have been conducted to evaluate safety and efficacy in children).

    Carefully:With caution, administer the drug to patients with persistent hyperthermia (above 38.5-39.0 ° C). Desensitizing and antipyretic agents are used to prevent and stop the temperature reaction.
    Pregnancy and lactation:

    Studies to assess the safety and efficacy of use in pregnant women and during lactation were not conducted.

    Dosing and Administration:

    For intravenous administration:

    50 mg of the preparation (contents of 1 bottle) are dissolved in 250 ml of sterile 0.9% sodium chloride solution. Enter intravenously, drip, at a rate of 3 ml / min, 1-2 times a day. The daily dose of 50-100 mg.

    Depending on the clinical effect - from 1 to 10 times, with an interval of 12-24 hours. Single dose 50 mg. The course dose of the drug is from 50 to 500 mg.

    For endotracheal administration:

    A 0.1% solution of the drug is used. To do this, 50 mg of the drug is diluted in 50 ml of 0.9% sodium chloride solution.

    5 ml 0.1% solution of the drug 2 times a day by irrigation of the tracheostomy and injection of 2 ml of 0.1% solution into the T-tube every 2 hours. The maximum daily dose of 50 mg (1 bottle). The course dose of the drug is from 50 to 500 mg.

    Side effects:

    Possible short-term chills and a rise in temperature (up to 37.5-39.5 ° C) 30-60 minutes after the infusion, allergic reactions.

    Overdose:

    Symptoms: hyperthermal reaction of varying degrees of severity.

    Treatment: desensitizing and antipyretic agents.

    Interaction:

    Interactions with other drugs have not been identified.

    Special instructions:

    Intravenous administration of the drug is recommended only in a hospital.

    To maintain the therapeutic concentration of the drug, intravenous infusions of other drugs are recommended after completion of infusion of the drug Laprot®.

    Form release / dosage:Lyophilizate for the preparation of a solution for infusions and endotracheal administration.
    Packaging:

    50 mg of active substance per 100 ml bottle for blood.

    For 1 bottle of 100 ml each, along with instructions for use, is placed in a cardboard box.

    Storage conditions:

    In a dry, dark place, out of the reach of children, at temperatures between 0 and 10 ° C.

    Shelf life:

    2 years.

    Do not use after the time specified on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-002374
    Date of registration:18.05.2012 / 20.05.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:NTFarma Ltd.NTFarma Ltd. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp15.02.2018
    Illustrated instructions
      Instructions
      Up